Ligand Pharmaceuticals | LGND - Selling And Administration Expenses


Ligand Pharmaceuticals reported $28.45M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Agenus USD 10.56M 13.04M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
Baxter International USD 761M 53M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Enviri Corporation USD 104.1M 10.81M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 212.48M 26.11M Dec/2025
Intrexon USD 10.31M 41K Jun/2024
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Merck USD 2.85B 215M Dec/2025
Pacira USD 91.87M 70K Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Veracyte USD 43.31M 8.43M Dec/2025